title: Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: The Challenge That Lies Ahead.
authors.affiliation: Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
authors.forename: Irina
authors.initials: I
authors.lastname: Amitai
authors.forename: Avi
authors.initials: A
authors.lastname: Leader
authors.forename: Pia
authors.initials: P
authors.lastname: Raanani
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases